Dataset Information

NUDT2 Knockout full proteome mouse

ABSTRACT: Proteome comparison between bone-marrow cells isolated from wildtype and NUDT2 knockout mice.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Bone Marrow, Bone Marrow Cell

DISEASE(S): Disease Free

SUBMITTER: Quirin Emslander

LAB HEAD: Andreas Pichlmair

PROVIDER: PXD023219 | Pride | 2021-11-03

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20170630_QEp5_BeLa_SA_3578_1.raw	Raw
	20170630_QEp5_BeLa_SA_3583_3.raw	Raw
	20170630_QEp5_BeLa_SA_3586_1.raw	Raw
	20170630_QEp5_BeLa_SA_3603_2.raw	Raw
	20170630_QEp5_BeLa_SA_3673_2.raw	Raw

Items per page:

1 - 5 of 57

Publications

NUDT2 initiates viral RNA degradation by removal of 5'-phosphates.

Laudenbach Beatrice T BT Krey Karsten K Emslander Quirin Q Andersen Line Lykke LL Reim Alexander A Scaturro Pietro P Mundigl Sarah S Dächert Christopher C Manske Katrin K Moser Markus M Ludwig Janos J Wohlleber Dirk D Kröger Andrea A Binder Marco M Pichlmair Andreas A

Nature communications 20211125 1

While viral replication processes are largely understood, comparably little is known on cellular mechanisms degrading viral RNA. Some viral RNAs bear a 5'-triphosphate (PPP-) group that impairs degradation by the canonical 5'-3' degradation pathway. Here we show that the Nudix hydrolase 2 (NUDT2) trims viral PPP-RNA into monophosphorylated (P)-RNA, which serves as a substrate for the 5'-3' exonuclease XRN1. NUDT2 removes 5'-phosphates from PPP-RNA in an RNA sequence- and overhang-independent man ...[more]

PMID: 34824277

Similar Datasets

Project description:Conventional anti-cancer drug screening is typically performed in the absence of accessory cells (e.g. stromal cells) of the tumor microenvironment, which can profoundly alter anti-tumor drug activity. To address this major limitation, we have developed assays (e.g. the tumor cell-specific in vitro bioluminescence imaging (CS-BLI) assay) to selectively quantify tumor cell viability, in presence vs. absence of non-malignant stromal cells or drug treatment. These assays have allowed us to identify that neoplastic cells from diverse malignancies exhibit stroma-induced resistance to different anti-tumor agents. In this analysis, we evaluated the molecular changes triggered in myeloma cells by their in vitro interaction with stromal cells. The transcriptional profile of 3 human multiple myeloma (MM) cell lines (MM.1S, MM.1R, INA-6) co-cultured with stromal cells vs. when cultured alone was characterized by oligonucleotide microarray analysis, using the human U133 plus 2.0 Affymetrix GeneChip. Three human multiple myeloma (MM) cell lines (MM.1S, MM.1R, INA-6) stably expressing green fluorescent protein (GFP) were cultured in vitro for 24hrs either alone or in the presence of the human bone marrow stromal cell line HS-5. Fluorescence activated cell sorting was used to separate the GFP+ MM cells from GFP- stromal cells. The gene expression profiles of MM cells after their co-culture with stromal cells were compared with the profiles of MM cells cultured alone, according to previously described protocols for total RNA extraction and purification; cDNA synthesis; production of biotin-labeled cRNA; hybridization of cRNA with U133plus2.0 Affymetrix gene chips; and scanning of image output files. Scanned image output files were analyzed using DNA-Chip Analyzer (dChip) (www.dchip.org), including conversion to DCP files, normalization and modeling, and averaging of duplicate chips according to standard parameters recommended by the software. For each cell line, the gene expression profile in the presence of stomal cells was compared to the profile of the same cell line cultured in the absence of stromal cells. Technical replicates for each condition were analyzed (total of 12 gene expression profiles).